Search research articles
Contact Us
Filters
Showing results (201-210 of 222) with videos related to
Page
of 23
Sort By:
Investigational New Drugs
|
August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study
Donald A Richards, Paul R Kuefler, Carlos Becerra, et al.
Clinical Rheumatology
|
May 16, 2025
Prevalence of and risk factors for important comorbidities of systemic lupus erythematosus using data from a multicenter Chinese cohort registry: A cross-sectional study
Minhui Wang, Jiaxin Zhou, Feng Zhan, et al.
Frontiers in Medicine
|
October 7, 2022
Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus
Yue Shi, Dandan Bi, Yanhong Wang, et al.
Annals of the Rheumatic Diseases
|
February 16, 2022
Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
Shangyi Jin, Nan Jiang, Yuehong Huo, et al.
Frontiers in Psychiatry
|
October 10, 2022
Commentary: Targeting the MRI-mapped psychopathology of major psychiatric disorders with neurostimulation
Jia-Xin Xie, Jin-Jin Cui, Yang Cao, et al.
Zhonghua Yi Xue Za Zhi
|
April 12, 2014
[A multi-center retrospective study of organ involvement in adult patients with polymyositis or dermatomyositis]
Qianzi Zhan, Guochun Wang, Xiangyuan Liu, et al.
Arthritis Research & Therapy
|
January 12, 2021
Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
Yirong Xiang, Mengtao Li, Hui Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2010
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer
David Loesch, F Anthony Greco, Neil N Senzer, et al.
Clinical Colorectal Cancer
|
November 8, 2011
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
Leonard Saltz, Suprith Badarinath, Shaker Dakhil, et al.
Med (New York, N.Y.)
|
July 11, 2024
Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort
Yufang Ding, Yangzhong Zhou, Feng Zhan, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 222) with videos related to
Sort By:
Page
of 23
Investigational New Drugs
|
August 29, 2009
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study
Donald A Richards, Paul R Kuefler, Carlos Becerra, et al.
Clinical Rheumatology
|
May 16, 2025
Prevalence of and risk factors for important comorbidities of systemic lupus erythematosus using data from a multicenter Chinese cohort registry: A cross-sectional study
Minhui Wang, Jiaxin Zhou, Feng Zhan, et al.
Frontiers in Medicine
|
October 7, 2022
Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus
Yue Shi, Dandan Bi, Yanhong Wang, et al.
Annals of the Rheumatic Diseases
|
February 16, 2022
Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
Shangyi Jin, Nan Jiang, Yuehong Huo, et al.
Frontiers in Psychiatry
|
October 10, 2022
Commentary: Targeting the MRI-mapped psychopathology of major psychiatric disorders with neurostimulation
Jia-Xin Xie, Jin-Jin Cui, Yang Cao, et al.
Zhonghua Yi Xue Za Zhi
|
April 12, 2014
[A multi-center retrospective study of organ involvement in adult patients with polymyositis or dermatomyositis]
Qianzi Zhan, Guochun Wang, Xiangyuan Liu, et al.
Arthritis Research & Therapy
|
January 12, 2021
Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
Yirong Xiang, Mengtao Li, Hui Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2010
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer
David Loesch, F Anthony Greco, Neil N Senzer, et al.
Clinical Colorectal Cancer
|
November 8, 2011
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
Leonard Saltz, Suprith Badarinath, Shaker Dakhil, et al.
Med (New York, N.Y.)
|
July 11, 2024
Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort
Yufang Ding, Yangzhong Zhou, Feng Zhan, et al.
Page
of 23